Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung CancerScott Gettinger, Julie R. Brahmer, Scott Antonia et al.|Journal of Clinical Oncology|2015Cited by 1.2k
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving NivolumabDavid F. McDermott, Michael B. Atkins, Charles G. Drake et al.|Journal of Clinical Oncology|2015Cited by 443